Printer Friendly

BIO-IMAGING TECHNOLOGIES, INC. CEO JAMES J. CONKLIN, M.D., TO SPEAK AT MASSACHUSETTS GENERAL HOSPITAL ON BRAIN IMAGING AND DRUG DEVELOPMENT

 WEST TRENTON, N.J., April 22 /PRNewswire/ -- James J. Conklin, MD, CEO and Chairman of Bio-Imaging Technologies, Inc. (NASDAQ: BITI), will deliver a presentation on Advanced Neuroimaging Techniques for Drug Development on Friday, April 23, at Massachusetts General Hospital.
 Conklin will present as part of the Massachusetts General Hospital/ Harvard Medical School Department of Psychiatry-Clinical Psychopharmacology Unit's sixth annual series, "Advances in Psychopharmacology and Behavioral Neurobiology."
 This year's program is entitled "The Therapeutic Frontier: Drug Discovery and Development in Psychiatry."
 Conklin, a board-certified internist and nuclear medicine pecialist, is an expert on drug development applications of medical imaging and image processing technologies. Trained at Temple University School of Medicine and the Johns Hopkins Medical Institutions, Conklin has published over 150 articles, abstracts and reviews, and 2 books on medical imaging. Formerly, he was Director of the Armed Forces radiobiological Research Institute, the world's largest radiobiological research facility. Prior to co-founding Bio-Imaging Technologies, Conklin was VP, Product Development and Clinical Research and Development at Cytogen Corporation, and Director of Tumor, Cardiovascular Imaging and Infectious Disease Programs at Centocor, Inc.
 Conklin, has written extensively on the use of nuclear medicine, x-ray computed tomography, magnetic resonance imaging and fiberoscopic imaging techniques to facilitate the clinical evaluation of new diagnostic and
therapeutic agents. He co-founded Bio-Imaging


Technologies to assist pharmaceutical and biotechnology companies in the use of medical imaging technologies to facilitate the drug development process. As a member of the Corporate Council of The National Foundation for Brain Research, Bio-Imaging Technologies supports "Decade of the Brain" initiatives to advance neuroscience research.
 Conklin's presentation will focus on the use of such imaging techniques as MRI and PET to gain greater insight into how drugs for neurodegenerative and psychiatric disorders affect the human brain and ultimately, clinical outcomes. Conklin also calls for increased collaboration between academic researchers, industry and government to establish a map of brain function and anatomy that will aid the clinical evaluation of new treatments for brain disorders.
 Conklin has advocated a greater role for medical imaging and computer technologies as means to reduce the time and cost of drug development, particularly for central nervous system disease, cardiovascular disease and cancer.
 /delval/
 -0- 4/22/93
 /Editors: To arrange interviews, contact Mary Ellen Jordan, Bio- Imaging Technologies, Inc., Assistant to Dr. Conklin, 609-883-2000; or Ann M. Callahan, MD, Massachusetts General Hospital, Department of Psychiatry, Clinical Psychopharmacology Unit, Seminar Director, 617-726-3488/
 /CONTACT: John T. Keane, controller and CFO, 609-883-2000, or William L. Robbins, director, business development, 609-883-2000/
 (BITI)


CO: Bio-Imaging Technologies, Inc. ST: New Jersey, Massachusetts IN: MTC SU:

CC -- PH001 -- 9131 04/22/93 07:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:435
Previous Article:EVERY DAY IS DERBY DAY AT THE KENTUCKY DERBY MUSEUM
Next Article:SUN INCOME UP SHARPLY IN FIRST QUARTER
Topics:


Related Articles
BIO-IMAGING TECHNOLOGIES, INC. CEO JAMES J. CONKLIN, MD ELECTED AS A REGIONAL FINALIST IN 1993 ENTREPRENEUR OF THE YEAR AWARDS
BIO-IMAGING TECHNOLOGIES, INC. AWARDED CONTRACT BY AMERSHAM; COMPANIES TO COLLABORATE ON BRAIN IMAGING PROJECT
BIO-IMAGING TECHNOLOGIES, INC. REPORTS FISCAL 1993 RESULTS
BIO-IMAGING TECHNOLOGIES NAMES TERRENCE P. BRENNAN PRESIDENT AND CEO; FORMER PRESIDENT RESEARCH DATA CORP.
BIO-IMAGING TECHNOLOGIES, INC. ANNOUNCES RESULTS FOR THE FIRST QUARTER OF FISCAL 1994
BIO-IMAGING TECHNOLOGIES, INC. AND AMERSHAM INTERNATIONAL PLC SIGN CO-PROMOTION AGREEMENT FOR BRAIN IMAGING WITH CERETEC(TM)
BIO-IMAGING TECHNOLOGIES, INC. OUTLINES FISCAL 1994 MARKETING ACCOMPLISHMENTS AND STRATEGIC DIRECTION FOR 1995
BIO-IMAGING TECHNOLOGIES, INC. ANNOUNCES CHANGE IN SENIOR MANAGEMENT
BIO-IMAGING TECHNOLOGIES, INC. ANNOUNCES FIRST QUARTER, 1996 RESULTS; TERMINATES CO-MARKETING AGREEMENT WITH CORNING BESSELAAR INC.
Bio-Imaging Technologies, Inc. Announces Contract with Pharmacyclics, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters